Drugs / denintuzumab mafodotin
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01786096 | Feb 2013 → May 2017 | Burkitt lymphoma, precursor lymphoblastic lymphoma/leukemia | Seagen Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01786135 | Feb 2013 → Aug 2015 | Burkitt lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma +1 | Seagen Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02855359 | Aug 2016 → Jan 2018 | diffuse large B-cell lymphoma | Seagen Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT02592876 | Oct 2015 → Apr 2018 | diffuse large B-cell lymphoma | Seagen Inc. | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | denintuzumab mafodotin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02855359 ↗ |
| Known as | Denintuzumab mafodotina | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545371 ↗ |
| Known as | Denintuzumab mafodotine | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545371 ↗ |
| Known as | SGN-19A | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545371 ↗ |
| Known as | SGN-CD19A | “Part A: denintuzumab mafodotin (SGN-CD19A) + RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)” NCT02855359 ↗3“Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma” NCT02592876 ↗ |
| Route | Intravenous | “SGN-CD19A (IV) once (Day 1) or twice (Days 1 and 8) every 21 days” NCT01786096 ↗ |
| Target | CD19 | “B-lymphocyte antigen CD19 binding agent” CHEMBL3545371 ↗ |